Migraine Research in 2025: Breakthroughs and What's Next
For most of the twentieth century, migraine prevention ran on borrowed drugs. Blood pressure medications, antidepressants, anti-seizure drugs — all discovered to help migraine by accident, none designed for it. The triptans, arriving in the 1990s, were the first real exception: purpose-built for migraine from the serotonin-receptor work of the preceding decade. But they treated attacks already underway, and on the prevention side the borrowed-drug era continued.
That changed over the past decade, and by 2025 the shape of the field looked genuinely different — the first preventives designed specifically for migraine, a second acute drug class for people triptans never suited, and a deeper pipeline behind both than migraine research has ever had. This is a look at what changed, what it means in practice, and where the work is heading next.
The CGRP era
The central story is a molecule called calcitonin gene-related peptide, or CGRP — a neuropeptide involved in pain signalling and blood vessel dilation. Researchers noticed decades ago that CGRP levels rise during migraine attacks, and that infusing it could provoke an attack in people with migraine. The obvious question was whether blocking it would help.
Answering that took a long time and several failed attempts, but it worked. Two distinct drug classes came out of it.
CGRP monoclonal antibodies are preventive treatments given by injection, monthly or quarterly, or by IV infusion. Erenumab, fremanezumab, galcanezumab, and eptinezumab all target either CGRP itself or its receptor. They were the first preventive medications designed specifically for migraine, and the practical difference for patients was substantial — a preventive that doesn't come with the sedation, weight gain, or cognitive fog that made older options hard to stay on.
Gepants are small-molecule CGRP receptor blockers taken orally. Ubrogepant and rimegepant treat attacks in progress; atogepant is taken daily for prevention; rimegepant does both. Zavegepant added a nasal spray option. Two features made them significant: they work for many people who don't respond to triptans, and unlike triptans they don't constrict blood vessels — which opens acute treatment to people with cardiovascular conditions who couldn't safely take triptans at all.
A third class, the ditans — lasmiditan is the one on the market — targets a serotonin receptor subtype without vasoconstriction, another route to treating attacks in patients for whom triptans were off the table.
The cumulative effect is that "we've tried everything" means something quite different now than it did in 2015. A lot of people carrying that conclusion from an older assessment have options they've never been offered.
What the mechanism research established
Alongside the drugs, a slower shift happened in how migraine is understood — and it changed the clinical conversation.
Migraine is now firmly understood as a neurological disorder involving the trigeminovascular system and the brainstem, not primarily a vascular event. The old "blood vessels dilate and that's the headache" model doesn't survive the imaging evidence.
Studies of the premonitory phase — the hours or days before pain begins — found activity in the hypothalamus preceding attacks, along with the yawning, food cravings, mood changes, and neck stiffness many patients recognize. This reframed a couple of long-standing arguments. Chocolate, for one: rather than triggering attacks, cravings for it appear in some cases to be an early symptom of an attack already underway. It also suggests migraine begins well before anyone would call it a headache, which has implications for when treatment should start.
Cortical spreading depression — a slow wave of neuronal activity followed by suppression, moving across the cortex — is the accepted substrate of aura, and gives a mechanistic account of why aura looks the way it does.
And genetics confirmed what families already knew. Large genome-wide association studies have identified more than a hundred genetic loci associated with migraine risk, establishing it firmly as a polygenic condition. Rare single-gene forms exist too, notably familial hemiplegic migraine.
What's next
Several lines of work look genuinely promising rather than merely active.
PACAP. Pituitary adenylate cyclase-activating polypeptide is another neuropeptide that, like CGRP, can provoke migraine attacks when infused. It's the most-watched next target, particularly for the substantial group of patients who don't respond adequately to CGRP-based drugs, and antibodies against it have been in clinical development.
Neuromodulation devices. Several non-drug devices — targeting the vagus nerve, the trigeminal nerve, or using remote electrical neuromodulation at the arm — are already available. They matter most for people who can't tolerate medications, are pregnant, or are trying to reduce medication days to avoid overuse headache. Expect refinement of who benefits and how they're best combined with drugs.
Prediction and wearables. A growing body of work is trying to forecast attacks before they start, using physiological signals like heart rate variability, sleep patterns, and skin conductance, along with environmental data. The premonitory-phase findings are what make this plausible — there's a measurable window before the pain. Getting it accurate enough to act on is the open problem.
Better trigger science. Trigger research is being redone with more rigour, and the weather question is part of it. Barometric pressure has been studied in controlled settings, with some experimental work reporting that pressure reductions can provoke headache in susceptible people. The picture is complicated by a real difficulty: attacks that begin during the premonitory phase can be misattributed to whatever the person encountered afterwards. Distinguishing genuine triggers from coincidence and from early symptoms is a live methodological challenge, and one reason individual tracking data has become more interesting to researchers.
Precision medicine. The current approach to choosing a preventive is still largely trial and error over months. Work on biomarkers and genetic or clinical predictors of response aims to shorten that, and it would be one of the more meaningful practical advances available.
What this means for you
A few things follow from all of this.
If your last serious treatment review was more than a few years ago, it's out of date. The CGRP drugs and gepants either didn't exist or weren't widely prescribed. That alone justifies asking for a fresh assessment.
"Nothing works for me" is worth re-testing against the current menu. Non-response to triptans doesn't predict non-response to gepants or ditans — different mechanisms, different outcomes.
And your own data has more value than it used to. As research moves toward prediction and individualized triggers, a personal record of attacks and conditions is the input that makes any of it applicable to you specifically.
Where Pressure Pal fits
The forecasting direction in the research is essentially what Pressure Pal is built around at a practical level: pairing a symptom log with an environmental signal that can be forecast in advance.
Pressure Pal tracks barometric pressure for your location and lets you log attacks against it. Over several weeks that produces the thing the trigger literature keeps pointing at — an individual record, rather than an average across a study population. Group averages can hide the fact that some people are strongly weather-sensitive and others aren't at all. Your log answers the question for you.
The practical payoff is the same one the wearable research is chasing: advance warning. If pressure is forecast to drop sharply tomorrow and your history says that's a high-risk pattern for you, you can act on it — protect your sleep, keep acute medication accessible, ease the day's demands.
Bottom line
Migraine research moved from borrowed drugs to designed ones, and from a vascular theory to a neurological one, in roughly a decade. CGRP-targeting treatments are the headline, PACAP and attack prediction are the most promising next steps, and the practical takeaway for anyone living with migraine is that an old "we've tried everything" verdict deserves revisiting. The field is moving faster than most patients have been told.
This article is for general education and isn't a substitute for professional care. Treatment availability and approvals vary by country. Discuss any treatment decisions with a qualified healthcare professional.